<DOC>
	<DOCNO>NCT02434757</DOCNO>
	<brief_summary>This small study investigate efficacy safety Acthar adjunct therapy patient active rheumatoid arthritis ( RA ) inadequate response disease modify antirheumatic drug ( DMARDs ) least 3 biologic agent . An adequate response define ≥ 6 tender joint , ≥ 6 swollen joint , plus C-Reactive Protein ( CRP ) level and/or erythrocyte sedimentation rate ( ESR ) ≥ 1.2 time upper limit normal spite aggressive treatment , include ≥ 7.5 mg/d prednisone . This 20 week , prospective , multicenter , open-label study conduct 3-4 university/medical center private practice setting US . A total 20 eligible patient enrol standard RA therapeutic agent , Methotrexate , DMARDs , non-steroidal anti-inflammatory drug ( NSAIDs ) , pain medication others discontinue . The primary endpoint percentage patient reduction ≥1.2 point Disease Activity Score 28 joint ( DAS-28 ) score .</brief_summary>
	<brief_title>Addition H.P . Acthar Gel Treatment Regimen Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>&gt;</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>≥ 18 year age time participation Have confirm diagnosis RA base 2010 ACR/EULAR criterion Currently aggressive treatment inadequate response AE stable dose DMARDs biologic agent 3 month prior screen , stable dos NSAIDs , prednisone equivalent dose corticosteroid ( dose ≥7.5 mg/d ) , analgesic 28 day prior screen . Have active RA , define ≥6 swollen joint , ≥6 tender joint , plus CRP level /or ESR ≥1.2 upper limit normal RA art least 24 month receive maximum tolerated dos lease 3 biologic agent ( least 1 antiTNFa ) 3 month Tuberculosis occur within recent past , proven conventional xray , negative tuberculosis shin test ( PPD ) , quantiferon gold Presence condition could confound interpretation data , inflammatory arthritis ( eg . psoriatic arthritis , gout pseudogout ) Presence systemic fungal infection , recent surgery ( within prior 3 month ) , active ulcer disease ( within past 5 year ) Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurological cerebral disease Have last three month plan receive live live attenuate vaccine Concomitant medical condition , opinion investigator , might place subject unacceptable risk participation study uncontrolled diabetes hypertension History presence active latent tuberculosis ( TB ) base QuantiFERONTB gold test . Patients allow study receive adequate treatment TB Sensitivity proteins porcine origin History cancer within last 5 year , exclude basal cell carcinoma Glomerular filtration rate &lt; 30 mL/min Uncontrolled diabetes mellitus Pregnant lactate female patient . Each site administer pregnancy test female childbearing potential prescribing Acthar Gel . Only females negative pregnancy test result eligible . All sexually active male female childbearing potential must agree use adequate method contraception throughout period study . The following physical laboratory test finding Patients positive hepatitis B surface antigen Patients positive hepatitis C antibody , also positive recombinant immunoblot assay ( RIBA ) polymerase chain reaction ( PCR ) Hemoglobin level &lt; 8.5 . g/dL White blood cell count &lt; 3000/mm ( 3 x 10/L ) Serum Creatinine level &gt; 2 time upper limit normal Serum alanine aminotransferase ( ALT ) asparate amino transferase ( AST ) &gt; 2 time upper limit normal Any laboratory test result , opinion investigator might place patient unacceptable risk participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>